Pen­ny stock play­er to re­view all op­tions to try stay­ing afloat af­ter clin­i­cal tri­al fail

Adamis Phar­ma­ceu­ti­cals is slow­ly tum­bling down, and the biotech is look­ing at all its op­tions.

Af­ter a Phase II/III tri­al fail­ure last month that sent the pen­ny stock play­er down an ad­di­tion­al 50% to just 15 cents a share, the com­pa­ny said Mon­day that it is ex­am­in­ing op­tions to get the best val­ue for its in­vestors. A state­ment from Adamis in­di­cates that al­ter­na­tives in­clude any­thing from a part­ner­ship to a sale of Adamis’ two com­mer­cial prod­ucts, Zimhi and Sym­jepi.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER